{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:38:51Z","timestamp":1791041931656,"version":"4.1.0"},"reference-count":41,"publisher":"Japan Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1507\/endocrj.ej19-0371","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T18:03:56Z","timestamp":1586369036000},"page":"803-818","source":"Crossref","is-referenced-by-count":24,"title":["Long-term efficacy and safety of two doses of Norditropin&lt;sup&gt;\u00ae&lt;\/sup&gt; (somatropin) in Noonan syndrome: a 4-year randomized, double-blind, multicenter trial in Japanese patients"],"prefix":"10.1507","volume":"67","author":[{"given":"Reiko","family":"Horikawa","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo 157-8535, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Ogata","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Research Institute, National Center for Child Health and Development, Tokyo 157-8535, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Yokoya","sequence":"additional","affiliation":[{"name":"Thyroid and Endocrine Center, Fukushima Global Medical Science Center, Fukushima Medical University, Fukushima 960-1295, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Ogawa","sequence":"additional","affiliation":[{"name":"CMR Development Division, Novo Nordisk Pharma Ltd., Tokyo 100-0005, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Nishijima","sequence":"additional","affiliation":[{"name":"CMR Development Division, Novo Nordisk Pharma Ltd., Tokyo 100-0005, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Endo","sequence":"additional","affiliation":[{"name":"CMR Development Division, Novo Nordisk Pharma Ltd., Tokyo 100-0005, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Ozono","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Aoki Y, Niihori T, Inoue S, Matsubara Y (2016) Recent advances in RASopathies. J Hum Genet 61: 33\u201339.","DOI":"10.1038\/jhg.2015.114"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y (2008) The RAS\/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum Mutat 29: 992\u20131006.","DOI":"10.1002\/humu.20748"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Chen PC, Yin J, Yu HW, Yuan T, Fernandez M, et al. (2014) Next-generation sequencing identifies rare variants associated with Noonan syndrome. Proc Natl Acad Sci U S A 111: 11473\u201311478.","DOI":"10.1073\/pnas.1324128111"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4 Roberts AE, Allanson JE, Tartaglia M, Gelb BD (2013) Noonan syndrome. Lancet 381: 333\u2013342.","DOI":"10.1016\/S0140-6736(12)61023-X"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, et al. (2007) Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 39: 70\u201374.","DOI":"10.1038\/ng1926"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6 Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, et al. (2010) Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics 126: 746\u2013759.","DOI":"10.1542\/peds.2009-3207"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Kruszka P, Porras AR, Addissie YA, Moresco A, Medrano S, et al. (2017) Noonan syndrome in diverse populations. Am J Med Genet A 173: 2323\u20132334.","DOI":"10.1002\/ajmg.a.38362"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Noonan JA, Raaijmakers R, Hall BD (2003) Adult height in Noonan syndrome. Am J Med Genet A 123A: 68\u201371.","DOI":"10.1002\/ajmg.a.20502"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Lee CK, Chang BS, Hong YM, Yang SW, Lee CS, et al. (2001) Spinal deformities in Noonan syndrome: a clinical review of sixty cases. J Bone Joint Surg Am 83: 1495\u20131502.","DOI":"10.2106\/00004623-200110000-00006"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Ko JM, Kim JM, Kim GH, Yoo HW (2008) PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome. J Hum Genet 53: 999\u20131006.","DOI":"10.1007\/s10038-008-0343-6"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Lee BH, Kim JM, Jin HY, Kim GH, Choi JH, et al. (2011) Spectrum of mutations in Noonan syndrome and their correlation with phenotypes. J Pediatr 159: 1029\u20131035.","DOI":"10.1016\/j.jpeds.2011.05.024"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Niihori T, Nagai K, Fujita A, Ohashi H, Okamoto N, et al. (2019) Germline-activating RRAS2 mutations cause Noonan syndrome. Am J Hum Genet 104: 1233\u20131240.","DOI":"10.1016\/j.ajhg.2019.04.014"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Noonan JA (2006) Noonan syndrome and related disorders: alterations in growth and puberty. Rev Endocr Metab Disord 7: 251\u2013255.","DOI":"10.1007\/s11154-006-9021-1"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Ranke MB, Heidemann P, Knupfer C, Enders H, Schmaltz AA, et al. (1988) Noonan syndrome: growth and clinical manifestations in 144 cases. Eur J Pediatr 148: 220\u2013227.","DOI":"10.1007\/BF00441408"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Noordam C, van der Burgt I, Sweep CG, Delemarre-van de Waal HA, Sengers RC, et al. (2001) Growth hormone (GH) secretion in children with Noonan syndrome: frequently abnormal without consequences for growth or response to GH treatment. Clin Endocrinol (Oxf) 54: 53\u201359.","DOI":"10.1046\/j.1365-2265.2001.01188.x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Binder G, Neuer K, Ranke MB, Wittekindt NE (2005) PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome. J Clin Endocrinol Metab 90: 5377\u20135381.","DOI":"10.1210\/jc.2005-0995"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Seo GH, Yoo HW (2018) Growth hormone therapy in patients with Noonan syndrome. Ann Pediatr Endocrinol Metab 23: 176\u2013181.","DOI":"10.6065\/apem.2018.23.4.176"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Ferreira LV, Souza SA, Arnhold IJ, Mendonca BB, Jorge AA (2005) PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome. J Clin Endocrinol Metab 90: 5156\u20135160.","DOI":"10.1210\/jc.2004-2559"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Limal JM, Parfait B, Cabrol S, Bonnet D, Leheup B, et al. (2006) Noonan syndrome: relationships between genotype, growth, and growth factors. J Clin Endocrinol Metab 91: 300\u2013306.","DOI":"10.1210\/jc.2005-0983"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Noonan JA, Kappelgaard AM (2015) The efficacy and safety of growth hormone therapy in children with noonan syndrome: a review of the evidence. Horm Res Paediatr 83: 157\u2013166.","DOI":"10.1159\/000369012"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Noordam C, Peer PG, Francois I, De Schepper J, van den Burgt I, et al. (2008) Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11. Eur J Endocrinol 159: 203\u2013208.","DOI":"10.1530\/EJE-08-0413"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Ogawa M, Moriya N, Ikeda H, Tanae A, Tanaka T, et al. (2004) Clinical evaluation of recombinant human growth hormone in Noonan syndrome. Endocr J 51: 61\u201368.","DOI":"10.1507\/endocrj.51.61"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Osio D, Dahlgren J, Wikland KA, Westphal O (2005) Improved final height with long-term growth hormone treatment in Noonan syndrome. Acta Paediatr 94: 1232\u20131237.","DOI":"10.1111\/j.1651-2227.2005.tb02081.x"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Romano AA, Dana K, Bakker B, Davis DA, Hunold JJ, et al. (2009) Growth response, near-adult height, and patterns of growth and puberty in patients with noonan syndrome treated with growth hormone. J Clin Endocrinol Metab 94: 2338\u20132344.","DOI":"10.1210\/jc.2008-2094"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Raaijmakers R, Noordam C, Karagiannis G, Gregory JW, Hertel NT, et al. (2008) Response to growth hormone treatment and final height in Noonan syndrome in a large cohort of patients in the KIGS database. J Pediatr Endocrinol Metab 21: 267\u2013273.","DOI":"10.1515\/JPEM.2008.21.3.267"},{"key":"26","unstructured":"26 PMDA Japan: Norditropin<sup>\u00ae<\/sup> FlexPro<sup>\u00ae<\/sup> 5 mg, 10 mg, 15 mg for injection (Human growth hormone [genetical recombination] preparation). Japanese package insert."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Ozono K, Ogata T, Horikawa R, Matsubara Y, Ogawa Y, et al. (2018) Efficacy and safety of two doses of Norditropin<sup>\u00ae<\/sup> (somatropin) in short stature due to Noonan syndrome: a 2-year randomized, double-blind, multicenter trial in Japanese patients. Endocr J 65: 159\u2013174.","DOI":"10.1507\/endocrj.EJ17-0313"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 World Medical Association (October 2008) Declaration of Helsinki\u2014Ethical Principles for Medical Research Involving Human Subjects. Last amended by the 59th WMA General Assembly, Seoul, Republic of Korea.","DOI":"10.1515\/9783110208856.233"},{"key":"29","unstructured":"29 International Conference on Harmonisation (May 1996) ICH Harmonised Tripartite Guideline. Good Clinical Practice."},{"key":"30","unstructured":"30 Ministry of Health and Welfare (1997) MWH Ordinance on GCP (MHW Ordinance no. 28)."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 van der Burgt I (2007) Noonan syndrome. Orphanet J Rare Dis 2: 4.","DOI":"10.1186\/1750-1172-2-4"},{"key":"32","unstructured":"32 Ito Y, Kato N, Tachibana K, Fujieda K (2005) The year 2000 version of standard growth table and chart based on the standard height adopted by national treatment research project for chronic pediatric disease. Shonika Shinryo 68: 1343\u20131351 (in Japanese)."},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Marshall WA, Tanner JM (1969) Variations in pattern of pubertal changes in girls. Arch Dis Child 44: 291\u2013303.","DOI":"10.1136\/adc.44.235.291"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Marshall WA, Tanner JM (1970) Variations in the pattern of pubertal changes in boys. Arch Dis Child 45: 13\u201323.","DOI":"10.1136\/adc.45.239.13"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, et al. (2010) Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig 1: 212\u2013228.","DOI":"10.1111\/j.2040-1124.2010.00074.x"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Suwa S, Tachibana K, Maesaka H, Tanaka T, Yokoya S (1992) Longitudinal standards for height and heigth velocity for Japanese children from birth to maturity. Clin Pediatr Endocrinol 1: 5\u201313.","DOI":"10.1297\/cpe.1.5"},{"key":"37","unstructured":"37 MacFarlane CE, Brown DC, Johnston LB, Patton MA, Dunger DB, et al. (2001) Growth hormone therapy and growth in children with Noonan\u2019s syndrome: results of 3 years\u2019 follow-up. J Clin Endocrinol Metab 86: 1953\u20131956."},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Lee PA, Ross J, Germak JA, Gut R (2012) Effect of 4 years of growth hormone therapy in children with Noonan syndrome in the American Norditropin Studies: Web-Enabled Research (ANSWER) Program<sup>\u00ae<\/sup> registry. Int J Pediatr Endocrinol 2012: 15.","DOI":"10.1186\/1687-9856-2012-15"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Jeong I, Kang E, Cho JH, Kim GH, Lee BH, et al. (2016) Long-term efficacy of recombinant human growth hormone therapy in short-statured patients with Noonan syndrome. Ann Pediatr Endocrinol Metab 21: 26\u201330.","DOI":"10.6065\/apem.2016.21.1.26"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Noordam K, van der Burgt I, Brunner HG, Otten BJ (2002) The relationship between clinical severity of Noonan\u2019s syndrome and growth, growth hormone (GH) secretion and response to GH treatment. J Pediatr Endocrinol Metab 15: 175\u2013180.","DOI":"10.1515\/JPEM.2002.15.2.175"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Pellegrin MC, Michelon D, Faleschini E, Germani C, Barbi E, et al. (2019) Glucose metabolism evaluated by glycated hemoglobin and insulin sensitivity indexes in children treated with recombinant human growth hormone. J Clin Res Pediatr Endocrinol 11: 350\u2013357.","DOI":"10.4274\/jcrpe.galenos.2019.2019.0281"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/67\/8\/67_EJ19-0371\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T23:30:58Z","timestamp":1598657458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/67\/8\/67_EJ19-0371\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej19-0371","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}